|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7806 News |
|
| «12...7891011121314151617...156157» |
- | Enrollment change, Trial withdrawal: Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes (clinicaltrials.gov) - Oct 27, 2017
P2, N=0, Withdrawn, Sponsor: Institut de Recherches Cliniques de Montreal
N=30 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment closed, Trial primary completion date: Brown Adipose Tissue in Type 1 Diabetes (clinicaltrials.gov) - Oct 27, 2017
P=N/A, N=11, Active, not recruiting, Sponsor: Per-Ola Carlsson
N=30 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Sep 2018
- | Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date, HEOR, Patient reported outcomes: Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)? (clinicaltrials.gov) - Oct 26, 2017
P=N/A, N=146, Recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Sep 2018 Trial primary completion date: Aug 2017 --> Aug 2018
- | bortezomib / Generic mfg.
Trial completion, Trial primary completion date: CAD0111: Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease (clinicaltrials.gov) - Oct 26, 2017
P2, N=25, Completed, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Trial primary completion date: Aug 2017 --> Aug 2018 Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Mar 2017
- | tofacitinib / Generic mfg.
Trial completion, Trial primary completion date: Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients (clinicaltrials.gov) - Oct 26, 2017
P4, N=25, Completed, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Mar 2017 Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Sep 2017 | Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Sep 2017
- | Trial primary completion date: CADI: Creative Arts Diabetes Initiative for Youth/Young Adults Transitioning to Adult Care (clinicaltrials.gov) - Oct 26, 2017
P=N/A, N=20, Recruiting, Sponsor: University of Manitoba
Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Sep 2017 | Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Sep 2017 Trial primary completion date: Sep 2017 --> Dec 2017
- | aHSCT / University of Calgary
Trial termination: SCT-NMO: Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica (clinicaltrials.gov) - Oct 25, 2017
P1/2, N=3, Terminated, Sponsor: University of Calgary
Trial primary completion date: Sep 2017 --> Dec 2017 Active, not recruiting --> Terminated; recruitment failure
- | Trial primary completion date: PBR28 PET and Inflammatory Arthritis (clinicaltrials.gov) - Oct 25, 2017
P=N/A, N=22, Active, not recruiting, Sponsor: University of Oxford
Active, not recruiting --> Terminated; recruitment failure Trial primary completion date: Aug 2017 --> Nov 2017
- | clopidogrel / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, IO biomarker: CLOPUS: Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous (clinicaltrials.gov) - Oct 25, 2017
P1/2, N=18, Completed, Sponsor: University Hospital, Bordeaux
Trial primary completion date: Aug 2017 --> Nov 2017 Active, not recruiting --> Completed | N=30 --> 18 | Trial primary completion date: Jan 2018 --> Sep 2017
- | Trial completion, Enrollment change: The Effect of High Intensity Interval Training on Cardiovascular Fitness in People With Progressive Multiple Sclerosis. (clinicaltrials.gov) - Oct 25, 2017
P=N/A, N=12, Completed, Sponsor: University of Glasgow
Active, not recruiting --> Completed | N=30 --> 18 | Trial primary completion date: Jan 2018 --> Sep 2017 Not yet recruiting --> Completed | N=20 --> 12
- | Enrollment change: Closed-loop Glucose Control for Automated Management of Type 1 Diabetes (clinicaltrials.gov) - Oct 25, 2017
P=N/A, N=11, Completed, Sponsor: Boston University Charles River Campus
Not yet recruiting --> Completed | N=20 --> 12 N=38 --> 11
- | Trial primary completion date: Sleep, Coping and Executive Functioning in Youth With Type 1 Diabetes (clinicaltrials.gov) - Oct 24, 2017
P=N/A, N=40, Enrolling by invitation, Sponsor: Yale University
N=38 --> 11 Trial primary completion date: Jun 2017 --> Dec 2017
- | Enrollment closed, Trial primary completion date: B1B: Bright 1 Bodies Weight Management Program (clinicaltrials.gov) - Oct 24, 2017
P=N/A, N=50, Active, not recruiting, Sponsor: Yale University
Trial primary completion date: Jun 2017 --> Dec 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Feb 2018
- | clopidogrel / Generic mfg.
Enrollment closed, Trial primary completion date, IO biomarker: CLOPUS: Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous (clinicaltrials.gov) - Oct 20, 2017
P1/2, N=30, Active, not recruiting, Sponsor: University Hospital, Bordeaux
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Feb 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Jan 2018
- | Enbrel (etanercept) / Pfizer, Amgen
Trial completion, Trial primary completion date: Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients (clinicaltrials.gov) - Oct 20, 2017
P1/2, N=7, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Jan 2018 Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Aug 2014
- | Simulect (basiliximab) / Novartis, Enbrel (etanercept) / Pfizer, Amgen, Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: Efficacy of Islet After Kidney Transplantation (clinicaltrials.gov) - Oct 20, 2017
P3, N=24, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Aug 2014 Active, not recruiting --> Completed
- | Enrollment change, Trial termination, Trial primary completion date: The Effects of Mediterranean Diet on Remission, Lipid Profile, Weight and Body Composition in Children and Adolescents With Newly Diagnosed Type 1 Diabetes (clinicaltrials.gov) - Oct 20, 2017
P=N/A, N=4, Terminated, Sponsor: Rabin Medical Center
Active, not recruiting --> Completed N=150 --> 4 | Recruiting --> Terminated | Trial primary completion date: Jun 2017 --> Jun 2016; Recruitment difficulties
- | Enrollment change, Trial withdrawal: An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms (clinicaltrials.gov) - Oct 20, 2017
P=N/A, N=0, Withdrawn, Sponsor: Profil Institut f
N=150 --> 4 | Recruiting --> Terminated | Trial primary completion date: Jun 2017 --> Jun 2016; Recruitment difficulties N=300 --> 0 | Not yet recruiting --> Withdrawn
- | BI 695500 (rituximab biosimilar) / Boehringer Ingelheim
Enrollment change, Trial termination: Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Oct 19, 2017
P3, N=293, Terminated, Sponsor: Boehringer Ingelheim
N=300 --> 0 | Not yet recruiting --> Withdrawn N=237 --> 293 | Completed --> Terminated; substance discontinued
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Enrollment change, Adherence: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) - Oct 19, 2017
P=N/A, N=96, Completed, Sponsor: AbbVie
N=237 --> 293 | Completed --> Terminated; substance discontinued Active, not recruiting --> Completed | N=140 --> 96
- | BI 695500 (rituximab biosimilar) / Boehringer Ingelheim
Trial termination: Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis (clinicaltrials.gov) - Oct 19, 2017
P3, N=91, Terminated, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed | N=140 --> 96 Completed --> Terminated; Substance discontinued
- || Rituxan (rituximab) / Roche
Trial completion: RAHIA: Rituximab in Auto-Immune Hemolytic Anemia (clinicaltrials.gov) - Oct 19, 2017
P3, N=32, Completed, Sponsor: Assistance Publique - H
Completed --> Terminated; Substance discontinued Active, not recruiting --> Completed
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change: RAVELOS: Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study (clinicaltrials.gov) - Oct 19, 2017
P=N/A, N=67, Terminated, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed N=180 --> 67
- | Trial completion, Trial primary completion date, HEOR: Randomized Crossover Study to Test the Impact of Using a Software for Smartphones and Tablets in Treating Type 1 Diabetes (clinicaltrials.gov) - Oct 19, 2017
P=N/A, N=55, Completed, Sponsor: Philippe Klee
N=180 --> 67 Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Aug 2017
- | Trial completion, Trial primary completion date: Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Oct 19, 2017
P=N/A, N=45, Completed, Sponsor: Assistance Publique - H
Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Aug 2017 Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Oct 2015
- | Trial completion: Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases (clinicaltrials.gov) - Oct 18, 2017
P=N/A, N=140, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Oct 2015 Active, not recruiting --> Completed
- |||| rivaroxaban / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: RAPS: Rivaroxaban for Antiphospholipid Antibody Syndrome (clinicaltrials.gov) - Oct 18, 2017
P4, N=81, Completed, Sponsor: St. Joseph's Healthcare Hamilton
Active, not recruiting --> Completed Recruiting --> Completed | N=150 --> 81 | Trial primary completion date: Dec 2016 --> Sep 2017
- Humira (adalimumab) / AbbVie
Enrollment change, Trial termination, Trial primary completion date: The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients (clinicaltrials.gov) - Oct 18, 2017
P3, N=21, Terminated, Sponsor: Heinrich-Heine University, Duesseldorf
Recruiting --> Completed | N=150 --> 81 | Trial primary completion date: Dec 2016 --> Sep 2017 N=30 --> 21 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> Sep 2017
- ||||||| Gvoke HypoPen (glucagon auto-injectable rescue pen) / Xeris Biopharma
Trial completion, Enrollment change: Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics (clinicaltrials.gov) - Oct 18, 2017
P3, N=80, Completed, Sponsor: Xeris Pharmaceuticals
N=30 --> 21 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> Sep 2017 Recruiting --> Completed | N=100 --> 80
- | Enrollment closed, Phase classification, Trial initiation date, Trial primary completion date: Diabeloop WP7 : Crossover Evaluation of the Safety and the Efficacy of Artificial Pancreas Diabeloop (WP7) (clinicaltrials.gov) - Oct 18, 2017
P=N/A, N=71, Active, not recruiting, Sponsor: Centre d
Recruiting --> Completed | N=100 --> 80 Not yet recruiting --> Active, not recruiting | Phase classification: P3 --> PN/A | Initiation date: Dec 2016 --> Mar 2017 | Trial primary completion date: Oct 2017 --> Feb 2018
- || Gvoke HypoPen (glucagon auto-injectable rescue pen) / Xeris Biopharma
Trial completion, Enrollment change: Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients (clinicaltrials.gov) - Oct 18, 2017
P3, N=31, Completed, Sponsor: Xeris Pharmaceuticals
Not yet recruiting --> Active, not recruiting | Phase classification: P3 --> PN/A | Initiation date: Dec 2016 --> Mar 2017 | Trial primary completion date: Oct 2017 --> Feb 2018 Recruiting --> Completed | N=24 --> 31
- | Trial completion: Clinical Trial of a Serious Game for Individuals With SCI/D (clinicaltrials.gov) - Oct 17, 2017
P=N/A, N=178, Completed, Sponsor: University of Michigan
Recruiting --> Completed | N=24 --> 31 Active, not recruiting --> Completed
- ||| AZD9567 / AstraZeneca
Trial completion: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567. (clinicaltrials.gov) - Oct 16, 2017
P1, N=64, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Recruiting --> Completed
- | Biomarker, Trial completion, Trial initiation date: Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia (clinicaltrials.gov) - Oct 16, 2017
P=N/A, N=145, Completed, Sponsor: University of Aarhus
Recruiting --> Completed Enrolling by invitation --> Completed | Initiation date: Sep 2014 --> Dec 2013
- | Nplate (romiplostim) / Amgen, Kyowa Kirin
Trial completion, Enrollment change, Trial primary completion date: Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Oct 13, 2017
P1/2, N=16, Completed, Sponsor: Kyowa Hakko Kirin China Pharmaceutical Co.,LTD.
Enrolling by invitation --> Completed | Initiation date: Sep 2014 --> Dec 2013 Recruiting --> Completed | N=24 --> 16 | Trial primary completion date: Dec 2017 --> Aug 2017
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Enrollment change, HEOR: AGIL: Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Oct 12, 2017
P=N/A, N=7199, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed | N=24 --> 16 | Trial primary completion date: Dec 2017 --> Aug 2017 Recruiting --> Completed | N=4500 --> 7199
- | Nerventra (laquinimod) / Active Biotech
Trial termination, Trial primary completion date: An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease (clinicaltrials.gov) - Oct 11, 2017
P2, N=209, Terminated, Sponsor: Teva Pharmaceutical Industries, Ltd.
Recruiting --> Completed | N=4500 --> 7199 Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> May 2017; Sponsor terminated RRMS studies as sufficient long term clinical data was collected for the study drug in the relevant dose.
- Betaseron (IFN-β-1b) / Bayer
Enrollment open, Patient reported outcomes: PROmyBETAapp: Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study (clinicaltrials.gov) - Oct 11, 2017
P=N/A, N=40, Recruiting, Sponsor: Bayer
Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> May 2017; Sponsor terminated RRMS studies as sufficient long term clinical data was collected for the study drug in the relevant dose. Not yet recruiting --> Recruiting
- | Trial completion: Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis (clinicaltrials.gov) - Oct 11, 2017
P1, N=20, Completed, Sponsor: Tisch Multiple Sclerosis Research Center of New York
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date, HEOR: QUALIMAIRAU: Auto-immune Diseases and Quality of Life (clinicaltrials.gov) - Oct 10, 2017
P=N/A, N=77, Completed, Sponsor: Centre Hospitalier Universitaire Dijon
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Mar 2017 --> Mar 2016
- | baclofen / Generic mfg.
Trial completion, Enrollment change: Respiratory Monitoring of Intrathecal Baclofen- a Feasibility Study (clinicaltrials.gov) - Oct 10, 2017
P=N/A, N=15, Completed, Sponsor: Solent NHS Trust
Recruiting --> Completed | Trial primary completion date: Mar 2017 --> Mar 2016 Recruiting --> Completed | N=23 --> 15
- | Trial primary completion date: EMOSOCIAL-MS: Emotional Processing, Family Life, Friendship and Social Integration in Patients With Multiple Sclerosis (clinicaltrials.gov) - Oct 9, 2017
P=N/A, N=90, Recruiting, Sponsor: University Hospital, Bordeaux
Recruiting --> Completed | N=23 --> 15 Trial primary completion date: Aug 2017 --> Sep 2018
- | Trial primary completion date: Screening of Subjects With Type I Diabetes to Determine Eligibility for Islet Transplantation (clinicaltrials.gov) - Oct 9, 2017
P=N/A, N=600, Recruiting, Sponsor: Rodolfo Alejandro
Trial primary completion date: Aug 2017 --> Sep 2018 Trial primary completion date: Apr 2018 --> Apr 2019
- | cevidoplenib (SKI-O-703) / Oscotec
Trial completion: Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers (clinicaltrials.gov) - Oct 9, 2017
P1, N=48, Completed, Sponsor: Oscotec Inc.
Trial primary completion date: Apr 2018 --> Apr 2019 Recruiting --> Completed
- ||||||| Metoject (methotrexate autopen) / Medac
Trial completion, Compliance: Self-i: Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe (clinicaltrials.gov) - Oct 6, 2017
P3, N=278, Completed, Sponsor: Nordic Pharma SAS
Recruiting --> Completed Active, not recruiting --> Completed
- | sirolimus / Generic mfg.
Trial completion: Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy (clinicaltrials.gov) - Oct 5, 2017
P2, N=12, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial primary completion date: High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases (clinicaltrials.gov) - Oct 5, 2017
P=N/A, N=15, Suspended, Sponsor: Stanford University
Active, not recruiting --> Completed Trial primary completion date: Jun 2017 --> Jun 2018
- | Trial completion: SandRA: Cell Phone Based Automated Monitoring of Patients With Early Rheumatoid Arthritis (clinicaltrials.gov) - Oct 5, 2017
P=N/A, N=165, Completed, Sponsor: Medcare Oy
Trial primary completion date: Jun 2017 --> Jun 2018 Active, not recruiting --> Completed
- ||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial completion, Trial primary completion date: A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Oct 5, 2017
P1, N=52, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Nov 2017 --> Jun 2017
- || fingolimod / Generic mfg.
Enrollment closed, Phase classification, Enrollment change, Trial primary completion date: Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya (clinicaltrials.gov) - Oct 4, 2017
P=N/A, N=100, Active, not recruiting, Sponsor: McGill University
Active, not recruiting --> Completed | Trial primary completion date: Nov 2017 --> Jun 2017 Recruiting --> Active, not recruiting | Phase classification: P4 --> PN/A | N=400 --> 100 | Trial primary completion date: Nov 2019 --> Nov 2017